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Abstract: The Human Y chromosome (ChrY) has been demonstrated to be a powerful tool for
phylogenetics, population genetics, genetic genealogy and forensics. However, the importance of
ChrY genetic variation in relation to human complex traits is less clear. In this review, we summarise
existing evidence about the inherent complexities of ChrY variation and their use in association
studies of human complex traits. We present and discuss the specific particularities of ChrY genetic
variation, including Y chromosomal haplogroups, that need to be considered in the design and
interpretation of genetic epidemiological studies involving ChrY.
Keywords: Y chromosome; Y haplogroups; complex locus; genetic association analyses; genetic
epidemiology; complex human traits
1. Introduction
During the last decade, genome-wide association studies (GWASs) have identified large numbers
of loci associated with common complex human traits, enabling a better understanding of the genetic
architecture of human disease [1]. This progress is documented by the NHGRI-EBI GWAS Catalogue [2],
which includes all published GWAS hits to date. The latest version (accessed 11/10/20) of the widely
used diagram, “SNP-trait associations, mapped onto the human genome by chromosomal location and
displayed on the human karyotype”, provided by the catalogue (Figure 1), shows evidence of many
SNP–trait associations on all 22 autosomes and the X chromosome. Notably, however, none of the
GWAS hits found to date reside on the Y chromosome (ChrY).
Results from studies of various designs not limited to GWASs (e.g., candidate gene association
analyses) also provide evidence that minimises the role of ChrY common genetic variation in relation
to human complex traits. It is important to consider alternative explanations for this lack of association,
such as the inherent genetic complexity of ChrY, which differs from the remainder of human
chromosomes in terms of structure, function and population history. These differences make it
more complex to analyse than other human chromosomes, which consequently leads to the removal or
misanalysis of ChrY variants from association studies.
This review addresses specific features of human ChrY relevant for the design and interpretation
of genetic association studies of complex human traits and covers different study designs applied in
genetic epidemiological studies of ChrY, discussing their strengths and weaknesses, as well as potential
avenues for future research.
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Figure 1. GWASs can be used to look for genetic associations with human disease traits across the 
human genome. This figure is a modified version of the GWAS diagram from the September 2019 
version of the GWAS Catalog, a directory which contains more than 157,000 associations from 4,220 
publications [2]. The diagram shows hits identified on chromosomes 22 and X, with different 
categories of disease indicated by different coloured markers. There are no hits which correspond to 
ChrY. Legend has not been included for clarity, but the original diagram and legend can be found at 
https://www.ebi.ac.uk/gwas/diagram. 
2. The Human Y Chromosome, a Complex Locus for Complex Trait Analysis 
Since the discovery of ChrY in 1921 [3], specific particularities related to its structure, function 
and population history have been discovered. A comprehensive list can be found in Table 1. 
In summary, ChrY is the sex-determining chromosome in humans and is passed strictly from 
fathers to sons. Current understanding suggests that the function of ChrY is limited with regards to 
complex disease causal genes. Here we provide a review of the literature related to ChrY and complex 
diseases and also make suggestions for future studies. 
Table 1. Chronological order of the discovery of the particularities of the Y chromosome from the 
discovery of the male-determining region to exploration of gene function. 
Year  Description  References 
1985 ChrY utilised for evolutionary studies ‘genetic distance’ genealogy  [4] 
1986 
First evidence that the male-determining region is located on the short 
arm of the Y chromosome  [5] 
1989 ChrY polymorphisms utilised in phylogenetics [6] 
1990 First gene, sex-determining region Y (SRY), mapped onto ChrY  [7] 
1990 Animal models used to investigate the influence of ChrY on hypertension  [8] 
1991 Sry used in animal models to form transgenic mice [9] 
1997 ChrY utilised for forensic science and paternity testing   [10] 
2000 ChrY utilised for phylogenetics  [11] 
2000 
onwards  
Association between hind III restriction fragment polymorphism and 
cardiovascular disease detected [12–15] 
2002 Y-chromosomal haplogroups established [16] 
2003 MSY first sequenced [17] 
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2. The Human Y Chromosome, a Complex Locus for Complex Trait Analysis
Since the discovery of ChrY in 1921 [3], specific particularities related to its structure, function and
population history have been discovered. A comprehensive list can be found in Table 1.
Table 1. Chronological order of the discovery of t e partic larities the Y chro osome from the
discovery of the male-determining region to exploration of gene function.
Year Description References
1985 ChrY utilised for evolutionary studies ‘genetic distance’ genealogy [4]
1986 First evidence that the male-determining region is located on the short arm of the Y chromosome [5]
1989 ChrY polymorphisms utilised in phylogenetics [6]
1990 First gene, sex-determining region Y (SRY), mapped onto ChrY [7]
1990 Animal models used to investigate the influence of ChrY on hypertension [8]
1991 Sry used in animal models to form transgenic mice [9]
1997 ChrY utilised for forensic science and paternity testing [10]
2000 ChrY utilised for phylogenetics [11]
2000
onwards Association between hind III restriction fragment polymorphism and cardiovascular disease detected [12–15]
2002 Y-chromosomal haplogroups established [16]
2003 MSY first sequenced [17]
2005
onwards Unconvincing vidence relating the MSY to cardiovascular disease risk is reported [18–21]
2009
onwards Y haplotypes utilised to investigate association between ChrY and other complex traits [22–24]
2016 Exploration of the function of genes identified on within MSY [25]
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In summary, ChrY is the sex-determining chromosome in humans and is passed strictly from
fathers to sons. Current understanding suggests that the function of ChrY is limited with regards to
complex disease causal genes. Here we provide a review of the literature related to ChrY and complex
diseases and also make suggestions for future studies.
2.1. Structure of Human Chromosome Y and Recombination
In mammals, gender is dictated by either the presence or absence of ChrY. This chromosome is
structurally unusual in relation to autosomes and, in humans, bears an extremely high quantity of
repetitive content. ChrY also contains heterochromatic, X-transposed, X-degenerate, ampliconic and
pseudoautosomal regions (PAR) [17], formed over time, as the previously autologous pair underwent
a sequence of large scale inversions and deletion events [26].
ChrY shows similarity with its counterpart, the X chromosome, at the pseudoautosomal regions
present at the telomeres (Figure 2). As a result, crossovers involving ChrY can only occur at these
regions. The remainder of ChrY (~95%) is referred to as the male-specific region of ChrY (MSY) [17],
previously known as the non-recombining region of Y (NRY) [11]. Variation of the MSY over generations
is contributed to by de novo mutations and both X-to-Y and Y-to-Y gene conversion [17,27–29]. One study
suggests an average of 600 nucleotides per ChrY in a newborn male have undergone Y-to-Y gene
conversion in recent human evolution [27]. Whilst significant, this amount of variation is relatively
small when compared with autosomes and, when accompanied by uniparental inheritance and lack of
crossing over, means that Y chromosome lineages are relatively easier to trace back through time than
autosomal lineages.
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2.2. The Functional Role of the Human Y Chromosome
It has been frequently suggested that the functional significance of ChrY is minimal. ChrY would
therefore represent a ‘functional wasteland’ and it would be destined to disappear from the nuclear
genome [30]. Although absence of evidence does not imply evidence of absence for ChrY [31], this has
contributed to the historical consideration of ChrY as a human chromosome with an insignificant
functional role.
2.2.1. Deterioration of the Y Chromosome
Current evidence suggests that deterioration of ChrY was initiated by the acquisition of a male
sex-determining function early in mammalian evolution and subsequently perpetuated by repression
of recombination. This lack of recombination is also partly responsible for the loss of much of the
ancestral gene content, by way of a phenomenon known as Muller’s ratchet [32]. As a consequence,
ChrY has acquired genes which relate to male-specific functions.
There is controversy about the consequences of ChrY deterioration. Some authors have argued that
it will inevitably lead to continued degradation and eventual disappearance of the human ChrY [33].
This argument sites evidence from parallel systems of sex determination (ZW) and comparisons with
other mammals [30,34,35]. In contrast, other authors site gene conversion within palindromes [17]
and a relative slowing of rate of gene decay in ChrY over recent millennia as evidence supporting
continuing evolution in current human populations [26,36].
Disentangling which of these opposed hypotheses better explains the recent evolution of ChrY
is an active area of research [37,38]. Unanswered questions to date include (a) to what extent is
direct comparison of equivalent but different genetic sex-determining systems, namely XY and ZW,
appropriate? (b) Does the comparison of ChrY from long-diverged species overlook the complexities of
its evolution and bring about misleading conclusions? (c) Would understanding the extent of genetic
deterioration of ChrY be relevant and informative for genetic association analyses?
The degradation of ChrY may represent a biological explanation for the reduced number of
functional loci on ChrY and hence a reduced number of associations found by association mapping
approaches. If this degradation continues, then one would expect further loss of functional elements
over time. Alternatively, it could be possible that degradation of ChrY has reached an equilibrium
implying that current functional elements are important for males and will be maintained in the
population over time.
2.2.2. Genetic Content of the Y Chromosome
The entirety of the Chr Y was first sequenced in 2003 by Skaletsky et al. who identified 78
protein-coding genes, encoding 27 distinct proteins or protein families [17]. However, current transcript-
and protein-level evidence suggests the presence of 64 protein-coding genes including genes on the
PAR (Ensembl BioMart; HGNC; CCDS, all accessed 11/10/20) [39–41]. When the MSY is considered
in isolation (i.e., the genes on PAR1 and PAR2 excluded), the region has 45 protein-coding genes
(Ensembl BioMart; neXtProt v2020-07-17; both accessed 11/10/20) excluding PRYP3 and TSPY9P
which are now thought to be pseudogenes (Table S1) (Human Protein Atlas, accessed 11/10/20) [42].
This number is considerably smaller than the number of genes harboured within the X chromosome
(n = 852) and all other autosomes (range n = 234–2059), making ChrY the chromosome with the least
number of protein-coding genes in humans (Ensembl BioMart, accessed 11/10/20).
In contrast to its lack of protein-coding genes, ChrY presents an unusually high level of structural
polymorphisms. ChrY is enriched with various types of repeat polymorphisms including SINEs,
endogenous retroviruses and segmental duplications [32].
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2.2.3. Gene Function of the Y Chromosome
The first genes identified on the MSY were found to be instrumental in initiating and maintaining
the male phenotype [5,7,9] and conferring male fertility [43,44]. These findings likely contributed to
the belief that the principal function of the MSY was to facilitate development and maintenance of the
male phenotype, and further, that it held little consequence for health in general. Although this has
been the consensus for some time, confidence in this hypothesis is dwindling. The functions of genes
encoded by ChrY have been summarised by Bellott et al. [45]. These functions range from histone
lysine demethylation, regulation of stem-cell self-renewal and translation, and protein modification
(such as the deubiquitinase USP9Y) [45,46]. Although our understanding of MSY and the role of these
genes is far from complete, it seems plausible that variation within these loci could influence fitness.
These findings have promoted a shift in thinking that has given way to an explosion of research
into ChrY and numerous studies have now been published that search for associations between the
MSY and male traits.
2.3. Specific Particularities of the MSY in Relation to Human Population History
The MSY is a powerful tool with which to investigate human population history [47–52]. In order
to design appropriate genetic association studies of human complex traits, one must possess an
appreciation of the specific particularities of the MSY. This fundamental requirement may also lead to
the discovery of novel applications of the MSY, promoting a deepening of our knowledge of human
population history and structure in relation to genetic architecture of human traits.
Firstly, the haploid nature of ChrY means that it has a smaller effective population size when
compared with either autosomes or the X chromosome, which have four times and three times greater
effective population sizes, respectively. As a result, ChrY is much more vulnerable to the effects of drift
(already a key dictator of the evolution of ChrY due to lack of recombination), which results in the
accentuation of the differentiation between populations from one generation to the next [53,54].
Secondly, the perspective offered by studying ChrY is representative of only males within a
population. This is comparable to reasoning applied when using mitochondrial DNA (mtDNA),
which is (thought to be) predominantly inherited through the female line [55–57]. A plethora of
demographic and sociocultural practices between males and females (for example patrilocality versus
matrilocality, polygamy and disparity in life expectancy [58]) have the potential to influence gene
flow in the population. If ChrY is considered in isolation, intricacies of population dynamics may be
missed [59]. Combining two data types (that of MSY and mtDNA) is considered more efficacious.
This contextual approach to the analysis of the MSY and its variation is in itself another application for
the MSY, which has allowed collation of more information about the variation in movement between
males and females over time [60–62].
Thirdly and importantly, there are key assumptions upon which many of the investigations
mentioned above are based—including that these markers are neutral. This assumption is being tested
in recent research which looks at whether variation in the MSY could confer significant differences
in fitness or affect complex traits [15,63]. In addition, Y chromosome data can be used to estimate
the time to most recent common ancestor (TMRCA) and, due to its inherently smaller population
size, the estimation given by using the Y chromosome should be proportionally more recent than the
time indicated by neutral markers found on autosomes or the X chromosome [54]. TMRCA estimates
based on ChrY are revised as the knowledge in the field increases. For example, it has been suggested
that TMRCA estimates given by ChrY data are even more recent than would be predicted and thus
provide possible evidence of natural selection acting on ChrY [54,64]. In fact, there is recent evidence
suggesting that natural selection is involved in the maintenance of genetic variation involving copy
number variants [65]. This is an area where some controversy remains, following the discovery of a
new lineage (haplogroup A00) in 2013, revisions of the estimated TMRCA have been suggested [66–69].
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3. Y Haplogroups
A key particularity of the MSY in relation to human population history is the existence of Y
haplogroups. This source of genetic variation, absent on autosomes, is created by the absence
of recombination on the MSY. Y haplogroups are defined as groups of similar Y haplotypes
(genetic markers that are inherited together) that share a common ancestor with a particular SNP
mutation (Figure 3).
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Y haplogroups have been identified and organised into a phylogenetic tree which is added to
and amended as new ChrY SNPs are discovered [16,70]. Currently, more than 300 haplogroups have
been id tified throughout the world and hav been studied as a means to investigate and underst nd
s veral aspects related to Genetics. Their use in genetic genealogy and forensics has been discussed at
length in recent reviews [71,72]. We briefly discuss here the use of Y haplogroups in phylogenetics and
pop lation genetics.
The use of Y ha logroups as a tool for informing investigation into early human and indeed
primat population history has been widely studied. By looking at common Y haplogroups an
the variation which they contain, it is possible to stimate the time f origin and hypothesise about
the m vement of their carriers across the globe. To this nd, climatic and archae logical data have
been analysed in conjunction with MSY insertion and deletion events [51,73,74], micros tellites [75]
a d minisatellites [76]. Analysis of the MSY has provided solid evidence about the origins and early
igration of Homo sapiens [47,77,78]; the identification of candidate founder haplotypes for numerous
populations [79] and the elucidation of intricacies f inter an intrapopulation d namics across the
globe, including suggestions of partitio and coalescence events nd previ usl unknown genetic
b ttlenecks [74,80].
I addition to the investigation of human population history, the MSY has been used to gather
information about more recent human de ogra hics. Analysis has allowed the identification of Y
haplotype clusters and their distribution thr ughout Europe [81–85]. These subdivisions within the
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population are a potential source of variation in disease risk and further studies incorporating this
aspect of variation could have important implications for using haplogroup data in the study of disease.
4. The Y Chromosome in Genetic Epidemiological Studies of Human Complex Traits
Genetic epidemiological studies involving ChrY aim to analyse the role of ChrY and environmental
factors in determining or influencing health and disease in families and in populations. To date,
a variety of human complex traits including behaviour and psychiatric traits [24], cancer risk [86,87],
autoimmunity [88,89] and HIV progression [23] have been interrogated to this end, but the relationship
between the human ChrY and cardiovascular risk is one of the best studied examples. There is
a recent review [90] covering many aspects of this relationship, and therefore, we will not cover
details here. Instead, we will present key aspects for consideration when utilising ChrY in genetic
epidemiological studies using studies that explore cardiovascular risk as examples. We will discuss
gender differences in relation to disease incidence and progression, study design and the use of Y
haplogroups in association mapping.
4.1. Gender Differences in Relation to Disease
The fact that females lack all ChrY-specific genes implies that ChrY does not contain genes essential
for survival. However, gender differences in disease incidence have been documented for many
conditions [91–93]. For example, females are more likely to suffer from certain systemic autoimmune
conditions such as systemic lupus erythematosus [94] and rheumatoid arthritis [95]. Conversely,
men are more likely to suffer from schizophrenia [92] and cardiovascular disease [93]. There are also
significant gender differences in progression of certain diseases [96,97]. It is likely that an interplay of
genetic and environmental factors explains these differences. Variables that have been identified thus
far include gender differences in lifestyle patterns (e.g., alcohol consumption, smoking and dietary
habits) [98], variation in hormonal levels during development [99], hormonal influence during adult
life [100] and many others such as pregnancy [101].
4.2. Study Design
Study design is key for the success of association mapping analyses [102]. The association mapping
study designs utilised to date to explore the relationship between genetic variation on ChrY and human
complex traits include linkage studies, candidate gene studies, animal models and genome-wide
association studies (GWASs). Table 2 summarises different aspects of each of these study designs
and examples where they have been applied to disentangle the genetic contribution of the MSY in
relation to human complex traits. Table 2 also shows the implicit assumptions of each study design,
their strengths and limitations and examples of published studies to help contextualise the contribution
of these association mapping approaches to current understanding of the relationship between MSY
and complex traits.
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Table 2. Basis of different study designs used to investigate the association between ChrY and complex traits, with strengths and limitations for consideration when
analysing findings.
Study
Design Basis Strengths Limitations Reference
Linkage
analysis
First-degree relatives are compared in order to
ascertain the potential for a genetic component of
disease susceptibility
1- Successful in the identification of highly
penetrant genetic variants related to Mendelian
traits or monogenic disorders
1- Limited application for complex traits due to the use of
individuals that share similar genetic and environmental
constituents, establishing true effects in multifactorial traits is
limited
[44]
Candidate
gene studies
A particular gene is studied based on biological
plausibility. Variation at this gene is investigated
in genetic association studies
1- Highly specific for genetic variation which
focuses on the MSY
1- Locus selected in absence of understanding of its function and
potential effects
2- Highly vulnerable to chance making conflicting evidence more
likely
[12–14,19–21,103]
Animal
models
Animal studies are used as a framework for
looking at human disease
1- Allows careful control and manipulation of both
genetic and external environment to isolate the
effects of the MSY
1- Application of animal models to human disease makes two key
assumptions that may be incorrect:
- -That disease process studied is the same in humans as in
other animals
- -That the MSY in other animals and that in humans
is equivalent
2- Application of studies using consomic strains is limited due to
confounding factors
[104–107]
GWAS
Case-control study design used to look for
common genetic variants more frequently
identified in those with particular diseases
1- Allows genotype-first analysis of the MSY for
which understanding of genetic content is limited
1- Sex chromosomes are routinely excluded from these study
types as the entirety of the MSY is effectively in linkage
disequilibrium
2- Haplotypes and haplogroups used as a basis for this type of
analysis may be flawed
3- Frequency of haplotypes within haplogroups in different
cohorts may be sufficiently different to dilute or exaggerate
relationships seen in other populations
[15,18,22,23,108–111]
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4.2.1. Genome-Wide Association Studies (GWASs)
Table 3 shows a summary of issues relevant to genetic association studies carried out using MSY
SNPs (including GWASs). These include statistical power, linkage disequilibrium patterns, population
stratification, presence of complex loci, colocalisation, pleiotropy, gene–gene interactions, gene/protein
expression and replication.
Although these aspects are also relevant to genetic association studies involving SNPs located
on autosomes, studies involving ChrY need to account for additional issues that are specific to the
genetic complexities of the MSY. These specific characteristics of ChrY open additional effects and
possible solutions to account for them in the design and interpretation of GWASs involving ChrY SNPs.
Table 3 summarises the implications of each of them on the interpretation of genetic association studies.
We also point to possible solutions to minimise their impact.
The current GWAS literature does not offer conclusive evidence for a role for the MSY in disease
susceptibility. Various potential reasons for this exist. For example, ChrY is excluded from most
GWASs. In fact, ChrY SNPs are excluded from some commonly used genotyping arrays [112].
Another reason is that some authors opt for to exclude ChrY SNPs from GWAS analyses. Of note
however, is that ChrY is routinely excluded from GWASs as all common variants in the MSY are
effectively in linkage disequilibrium (Table 3). Although more recently X has been more likely to be
included [113], this practice has left a dearth of evidence with respect to ChrY. For example, out of
more than 50 GWASs conducted over the last 10 years on chronic kidney disease, only one reported
results of ChrY analyses [112].
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Table 3. Considerations and possible solutions for genetic association studies carried out using SNPs in the MSY.
GWAS Features Y Chromosome vs.Autosomes Implication Possible Solution(s) References
Statistical power Only men inherit a Ychromosome ~50% reduction in sample size
1- Include the Y chromosome in GWASs—could be mandated by funders
2- Share GWAS summary results (e.g., via LD Hub, GWAS Catalogue)
3- Increase sample sizes
[2,112,115]
LD structure All the common variants inthe MSY are in LD
Identifying the causal variant is very
difficult
1- Larger sample sizes
2- Fine mapping by (i) sequencing the MSY and the associated region, (ii) carrying
out transethnic studies and/or (iii) Y-DNA haplogroup association studies
3- Functional analyses (e.g., single SNP editing)
[15,24,116]
Population stratification
Principal components
calculated using autosomal
SNPs are not applicable
Potential overadjustment and loss of
statistical power
1- Sensitivity analyses with and without genetic principal components
2- Sensitivity analyses with and without Y-DNA haplogroup information as a
covariate in (male-only) GWASs and looking for SNPs with significant differences in
effect sizes
[117–119]
Complex loci Many highly variable regionsand repetitive sequences Variant calling may not be accurate Only include variants called with high confidence [17]
Colocalisation of eQTL
and GWAS signals
No eQTLs identified for the Y
chromosome
GWAS-eQTL colocalisation analysis
cannot be carried out at present Initiate trans-ethnic eeGWASs and/or study rare variants on the Y chromosome [114]
Pleiotropy No conclusive GWAS signalidentified
Not much information to link potential
findings with other biological pathways
1- Initiate a consortium to identify associations on the MSY
2- Carry out PheWASs using all Y chromosomal SNPs (incl. rare variants) [2]
Gene–gene interactions
Very few examples identified
in autosomes. None with
SNPs on the Y chromosome
Almost no statistical power to detect
small effects
Hypothesis driven approaches (e.g., between SNPs associated with obesity/CVD
and SNPs in/near UTY—a gene expressed in non-gonadal tissues) [120]
Gene/protein Expression
Many MSY genes/proteins are
not expressed at detectable
levels in non-gonadal tissues
Identified associations are likely to be
biologically implausible if not expressed
in disease-relevant tissue
Query the Human Protein Atlas to check whether the putatively causal gene/protein
is active in a relevant tissue (Figure 4) [121]
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4.2.2. Expression Quantitative Trait Loci (eQTLs) and Protein Quantitative Trait Loci (pQTLs)
Currently, there are 45 protein-coding genes specific to the Y chromosome (i.e., excl. genes in the
pseudoautosomal regions; Ensembl BioMart, accessed: 11/10/20). These 45 genes code for 27 distinct
proteins/protein complexes [114].
If ChrY variants are included in a GWAS, any identified associations will need to be biologically
plausible. To aid the search for prime candidates for GWASs of common complex diseases,
we queried the Human Protein Atlas (v19.2; Ensembl v92) for all 45 genes [121] (using aliases
from Ensembl BioMart database [122] to make sure we captured all) in all tissues except the testis and
female-specific tissues (i.e., vagina, ovary and fallopian tubes). We also removed results marked with
"not detected"—indicating that the levels of expression, if any, were below the limit of detection. As a
positive control, we queried to confirm whether the proteins were detected in the testis; 27 distinct
proteins were detected (validated by transcript-level evidence): DDX3Y, ZFY, RPS4Y1, VCY1B, VCY,
CDY2B, TSPY2, RBMY1F, CDY1, CDY1B, CDY2A, UTY, DAZ3, DAZ1, EIF1AY, DAZ4, DAZ2, RBMY1J,
TSPY3, TSPY8, TSPY4, RBMY1A1, TSPY10, RBMY1E, RBMY1B, RBMY1D, and TSPY1.
The only proteins that were detectable outside of the testes by the Human Protein Atlas were
DDX3Y, ZFY, RPS4Y1, NLGN4Y, UTY, and EIF1AY, which would make them and eQTLs/pQTLs
affecting their expression prime candidates for non-fertility related diseases/traits (Figure 4). There are
three more proteins—KDM5D, USP9Y, TMSB4Y—which are putatively ubiquitously expressed as
determined by RNA-seq carried out by GTEx [114] but are not yet validated by the Human Protein
Atlas’ immunohistochemistry assays – and would thus also be candidates for non-fertility related
diseases/traits [63,114].
We further searched the literature (e.g., GTEx [114], BRAINEAC [123], and Blood eQTL server [124])
to identify eQTLs on the Y chromosome. However, we could not find any—reflecting the need for
further research in this area (Table 3).
When interpreting these findings, one must consider the limitations of the analysis carried out
by the Human Protein Atlas, which uses an antibody-detection method, inevitably dependent on
the accuracy of antibodies used [125]. In some cases, antibodies are not able to distinguish between
proteins in the same family [125]. For example, antibodies may fail to distinguish between RBMY1A1
and RBMY1B, two members of the same family, both located on ChrY; similarly, between E1F1AY
and E1F1AX which are located on ChrY and ChrX, respectively. However, the Human Protein
Atlas uses other lines of evidence for antibody verification, including transcript mRNA validation
(https://www.proteinatlas.org/about/antibody+validation). Secondly, investigation here is limited to
those genes that are ubiquitously expressed, there are other protein-coding genes whose proteins have
been detected outside the gonads but not ubiquitously which may be plausible targets for complex trait
analysis. For example, PCDH11Y, predominantly expressed in the brain [63], which could perhaps
influence brain related diseases or behavioural traits. Thirdly, as protein expression varies with
development, there may be ChrY gene expression which affects complex trait development, which is
undetectable by currently used methods because they are not expressed in adult tissues [114].
4.3. Use of Y Haplogroups in Genetic Association Studies of Common Complex Traits
Y chromosome (Y-DNA) haplogroups are more widely used in population genetics than
in genetic epidemiology, although associations between Y-DNA haplogroups and several traits,
including cardio-metabolic traits and psychiatric traits have been reported [20,24,110].
In contrast, non-recombining genetic variation, such as Y chromosomal (Y-DNA) haplogroups,
has rarely been considered in the design and interpretation of genetic association studies [82].
We have recently studied weather hidden stratification and/or differential phenotypic effects by Y-DNA
haplogroups could exist [118]. Y haplogroups can be used to stratify individuals in genetic association
analyses. To this end, we followed a two-stage approach. Firstly, we stratified individuals according to
their Y haplogroups and then tested for association between 32 autosomal BMI-related SNPs from
Speliotes et al. [126] and BMI within each haplogroup after adjusting for the top 10 genetic principal
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components. Although we found evidence suggestive of an interaction between haplogroup I and FTO
SNPs in ALSPAC, we could not fully replicate these findings in the 1958 Birth Cohort. Further studies
are needed.
Consideration of haplogroups in the design and interpretation of genetic association studies
of ChrY, could be a crucial and commonly omitted source of complexity. Potential caveats and
limitations are in addition to those listed on Table 3 and relate to novel issues on genetic complexity,
population structure and statistical power.
4.3.1. Genetic Complexity Inherent to Y Haplogroups
Y haplogroups are complex genetic variants that combine haplotypes sharing a common
ancestor [70]. As a consequence, individuals sharing the same haplogroup are genetically heterogeneous
in relation to single genetic common variation, including SNPs. This may have direct implications
for genetic association studies. A SNP signal identified in GWASs could be diluted or more difficult
to identify when studying Y haplogroups. Similarly, comparing individuals from different cohorts
that share the same haplogroup could represent an additional layer of heterogeneity. It is likely that
such individuals differ genotypically in relation to a number of SNPs, despite belonging to the same
haplogroup. This heterogeneity needs to be taken into account in the interpretation of results observed
from different populations, traits and haplogroups.
Alternatively, haplogroups could be well placed to capture the effect of combinations of two or
more SNPs. In fact, haplotypes can define functional units of genes [127]. Advantages of analysing
haplogroups in association studies would include the fact that genetic variation in populations is
organised into haplotypes and that combining SNPs into haplogroups reduces the dimension of
association tests and may augment statistical power.
4.3.2. Statistical Power Issues in Studies Involving Y Haplogroups
The increase in power resulting from combining SNPs into haplogroups has a differential effect
on different haplogroups. An illustration table from [24] shows the frequency of different haplogroups
observed from a European cohort. 72.1% of individuals belong to haplogroup R, the commonest
haplogroup in Europe, 19% to haplogroup I. The remaining 9% of individuals belong to 10 other
haplogroups. As a result, there is considerable within-study power heterogeneity for different
haplogroups. This is a common feature of most studies involving Y haplogroups.
This has implications for study design and interpretation. Some analyses combine these
heterogeneous haplogroups into a new group, whereas other simply remove them from the analyses.
Collapsing different haplogroups is not an optimal solution, since different mutations are likely to be
associated with a specific haplotypic background.
On occasion, studies report suggestive associations involving low-frequency haplogroups.
The inherent low power of these associations together with the aforementioned heterogeneity among
populations make replication of these signals difficult. This also applies to subgroups of common
haplogroups. Refining associations within a haplogroup by considering different subgroups (e.g., R1a1,
R1b1, R1b1b2, R1b1b2g, R1b1b2h . . . ) mirrors the power issue that we have previously shown.
4.3.3. Population Structure Particularities Specific to Y Haplogroups
Population samples of Y haplogroups present specific idiosyncrasies, different from population
samples of SNPs, that need to be taken into consideration in the design and interpretation of genetic
association studies.
Extensive population evidence shows that Y haplogroups (and specifically, genetic trees that
generated them) describe ChrY correctly from a population point of view. Evolutionary history of Y
haplogroups correlates with geography. The question, still unresolved, is whether this also creates an
association to biology, specifically, to genetic association with human complex traits. Interestingly,
a recent study which investigated the pattern of methylation amongst some Y haplogroups [128] has
Genes 2020, 11, 1273 13 of 19
identified haplogroup-specific methylation sites accompanied by SNPs, irrespective of geographical
origin. These results also prompt one to question whether evolutionary history of ChrY could correlate
with human complex trait variation independent of geography.
5. Conclusions
To date, there is little evidence supporting a role of human ChrY variation on human complex
traits. A possible reason for this is that ChrY variation is actually irrelevant in relation to human
complex traits. Alternatively, one could argue that the lack of evidence could be related to study design
and interpretation issues. Here, we have reviewed and presented here evidence that highlights the
complexities of this issue and disentangles relevant variables and their possible role.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4425/11/11/1273/s1,
Table S1: Characteristics of the 45 protein-coding genes located on the human Y chromosome.
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